Subtitle: Market Intelligence, Synthetic Lethality Programs, and High-Purity Reagents for CHD1-Targeted Epigenetic Drug Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CHD1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Recombinant Protein & Antigen | CHD1 Full-Length, ATPase Domain, and Mutant Domains. High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. | View CHD1 Products |
| Gene Delivery | CHD1 Promise-ORF / Lentivirus. Full-length ORF for stable cell lines. CMV promoter, puromycin selection. Native folding. | View CHD1 Products |
| Benchmark Ab | Anti-CHD1 Antibody. Recombinant positive control for degradation/expression assays. | View CHD1 Products |
| Validator | CHD1 siRNA Set (3 unique sequences). For knockdown verification and synthetic lethality confirmation. | View CHD1 Products |
| Paralog Control | CHD4 Protein (NuRD Complex). For selectivity assays vs. CHD family. High purity (>95%). | View CHD4 Products |
| Synthetic Lethal Partner | PARP1 Protein. Full-length for combination studies and pathway analysis. | View PARP1 Products |
| Pathway-related Target A | PTEN. Synthetic lethality partner; PTEN-deficient tumors rely on CHD1. | View PTEN Products |
| Pathway-related Target B | AR (Androgen Receptor). Critical co-regulator in prostate cancer progression. | View AR Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| ATPase Activity Measurement | Purified CHD1 ATPase Domain with verified ATP-binding capacity. High specific activity preparation for IC50 determination. |
| Nucleosome Remodeling Validation | Full-length CHD1 with intact chromodomains for substrate binding studies. Compatible with mononucleosome substrates and gel shift assays. |
| Domain-Specific Targeting (ATPase vs Chromodomain) | Domain-specific truncated proteins (ATPase-only, Chromodomain-only) available with >95% purity and mass spec verification. |
| Paralog Selectivity (CHD4/CHD2) | Homolog panel proteins (CHD2, CHD4) strictly verified by mass spec for counter-screening and selective inhibition assays. |
| PROTAC Degradation Validation | Sequence-verified Lentivirus for stable reporter cell line construction; anti-CHD1 antibodies for degradation readout (DC50, Dmax). |
| Synthetic Lethal Validation | CHD1 ORF Lentivirus + PARP1/PTEN proteins for rescue and combination assays; validated siRNA for specificity checks. |
| Lack of Reliable Controls / Off-Target Phenotypes | Recombinant Benchmark Antibodies and validated siRNA included to distinguish true on-target effects from off-target noise. |
Live CHD1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- View Active Clinical Trials
- Latest Inhibitor Research
- Latest Resistance Research
- Recent Patent Filings
Global Clinical Landscape & Future Outlook
The race for CHD1-targeted therapeutics is intensifying. Major players are shifting focus from traditional cytotoxic agents to synthetic lethal strategies exploiting CHD1 deficiency, particularly in PTEN-deficient prostate and breast cancers. First-generation PARP inhibitor combinations are reaching the clinic, while the next wave of R&D is targeting ATPase-domain inhibitors and PROTAC degraders for complete scaffolding ablation of CHD1 to prevent compensatory resistance mechanisms in castration-resistant prostate cancer (CRPC).
Competitive Modality & Indication Snapshot
Connect market trends to assay needs.
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (ATPase/Chromodomain Inhibitor) | Structural Genomics Consortium, Academic Labs, Early Biotech | Prostate Cancer, Breast Cancer (including PTEN-mutant) | Selectivity Assay (Need high-purity ATPase & Chromodomain proteins for SPR/DSF) |
| PROTAC / Targeted Degrader | Emerging Biotech, Targeted Protein Degradation Biotechs | Castration-Resistant Prostate Cancer (CRPC), Solid Tumors | Degradation Assay (Need Lentivirus for stable cell lines & Anti-CHD1 antibodies for DC50/Dmax) |
| Synthetic Lethal & Combination Therapy | Oncology Pharma Partners, Top Tier Pharma | BRCA-deficient Cancers, PTEN-mutant Advanced Solid Tumors | Pathway Validation (Need PARP1, PTEN, AR recombinant proteins; CHD1 siRNA for dual knockdown) |